I
Irene Cecchi
Researcher at University of Turin
Publications - 94
Citations - 1034
Irene Cecchi is an academic researcher from University of Turin. The author has contributed to research in topics: Antiphospholipid syndrome & Medicine. The author has an hindex of 14, co-authored 65 publications receiving 702 citations.
Papers
More filters
Journal Article
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
Savino Sciascia,Franco Aprà,Alessandra Baffa,Simone Baldovino,Daniela Boaro,Roberto Boero,Stefano Bonora,Andrea Calcagno,Irene Cecchi,Giacoma Cinnirella,Marcella Converso,Martina Cozzi,Paola Crosasso,Fabio De Iaco,Giovanni Di Perri,Mario Eandi,Roberta Fenoglio,Massimo Giusti,Daniele Imperiale,Gianlorenzo Imperiale,Sergio Livigni,Emilpaolo Manno,C. Massara,Valeria Milone,Giuseppe Natale,Mauro Navarra,Valentina Oddone,Sara Osella,Pavilio Piccioni,Massimo Radin,Dario Roccatello,Daniela Rossi +31 more
TL;DR: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option and an improvement in respiratory and laboratory parameters was observed, requiring future controlled trials to confirm the definite benefit with IL-6 target therapy.
Journal ArticleDOI
Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets.
Irene Cecchi,Iván Arias de la Rosa,Elisa Menegatti,Dario Roccatello,Eduardo Collantes-Estevez,Chary López-Pedrera,Nuria Barbarroja +6 more
TL;DR: The pathogenic role of neutrophils in RA, the effect of conventional treatments and biologic therapies, and the new, potential targets of neutophil-derived molecules for the treatment of RA are reviewed.
Journal ArticleDOI
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
Savino Sciascia,Massimo Radin,Jinoos Yazdany,Maria G Tektonidou,Irene Cecchi,Dario Roccatello,Maria Dall'Era +6 more
TL;DR: In this paper, the authors conducted a literature search to identify articles reporting clinical experience with the use of eculizumab in SLE patients, focusing on renal involvement, and reported promising results.
Journal ArticleDOI
Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial.
Carlos Perez-Sanchez,Maria Angeles Aguirre,Patricia Ruiz-Limon,Maria del Carmen Abalos-Aguilera,Yolanda Jimenez-Gomez,Iván Arias de la Rosa,Antonio Rodríguez-Ariza,Lucía Fernández del Río,José A. González-Reyes,P. Segui,Eduardo Collantes-Estevez,Nuria Barbarroja,Francisco Velasco,Savino Sciascia,Irene Cecchi,Maria José Cuadrado,José M. Villalba,Chary López-Pedrera +17 more
TL;DR: The results highlight the potential of Qred to modulate the overexpression of inflammatory and thrombotic risk markers in APS and suggest it might act as safe adjunct to standard therapies in APs.
Journal ArticleDOI
Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review
TL;DR: An overall estimated median prevalence of anti‐&bgr;2 GPI‐DI antibodies of 44.3% is reported in patients with APS and/or SLE and a significantly higher prevalence among patients withAPS compared with SLE alone, which might represent a promising tool when assessing thrombotic risk in patientsWith APS.